The 2017 BIO International Convention  (BIO 2017), hosted by the Biotechnology Innovation Organizatio (BIO), closed today after four days of immersive, compelling programming united under the theme of “Breakthrough.”  BIO 2017 recognized past, present and future biotech breakthroughs that heal, feed and fuel the world

Memorandum of Understanding for Cooperation continues the longstanding relationship between BIO and RDPAC and deepens our cooperative efforts.

Bill cracks down on false or deceptive patent demand letters, ensures urgently-needed fairness and finality in Patent Office post grant proceedings, eliminates diversion of PTO user fees, and helps American research-intensive companies protect their investments in innovation

Tech Transfer Has Supported Up to 4.2 Million Jobs Since 1996

At the 2017 BIO International Convention, cabinet-level appointees representing Texas, Massachusetts, Rhode Island, and Puerto Rico participated in the report's release by discussing bioscience industry economic development and state policies that have proven successful in assisting industry growth.

Regulatory Systems Must Be Consistent across Agencies and Based on Actual Risk  Washington, D.C. (June 20, 2017) – In comments submitted to the U.S. Depart of Agriculture (USDA) and U.S. Food and Drug Administration (FDA), the Biotechnology Innovation Organization (BIO) urges the Administration to take consistent and decisive steps to unleash the full potential of American bio-based innovation in food, feed, agriculture, and animal health. Doing so will reinforce the United States’ global leadership in these sectors and foster the creation of more well-paying jobs at innovative companies throughout the country.

Washington, DC (June 19, 2017) – Today, the Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry.  Concurrent with the adoption of these principles, BIO established a board-level WDDI Committee charged with working to foster workforce development, diversity, and inclusion at BIO and throughout the biotech industry.  The Committee will be chaired by Helen Torley, President & CEO of Halozyme, who is succeeding Julie Gerberding, Executive Vice President & Chief Patient Officer at Merck, who led the Committee as it developed BIO’s WDDI principles over the last year.

A new slate of officers and Board members were elected during the 2017 BIO International Convention.